Senators introduce nanotech bill
This article was originally published in The Tan Sheet
Executive Summary
Sens. Mark Pryor, D-Ark., and Benjamin Cardin, D-Md., introduce the Nanotechnology Safety Act of 2010, which tasks FDA with assessing the safety of the technology, the lawmakers announce in a Jan. 21 release. The bill would authorize $25 million annually from 2011 through 2015 to establish an FDA program to assess nanotechnology safety as used in everyday products, and to "develop best practices for companies who employ" nanotechnology, they say. Pryor explains that potential risks must be evaluated and that S. 2942 "will help ensure public safety and confidence in the marketplace," and support firms using the technology
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.